pSivida resubmits NDA for Iluvien; Lincoln Pharmaceuticals launches ARH1;

> pSivida, which develops sustained-release drug delivery products for treatment of back-of-the-eye diseases, has resubmited its new drug application for the investigational drug Iluvien, which treats diabetic macular edema. pSivida release

> India's Lincoln Pharmaceuticals launches its antimalarial drug ARH1, which uses "dose optimization technology" as its delivery system. Report

> Peter Cohan: Can SpringLeaf make chemo and outpatient treatment? Column

> The FDA has accepted a new drug application for Insys Therapeutics' Fentanyl SL Spray, a sublinqual delivery system for cancer patients suffering from pain. Item

> Bio-Path Holdings uses liposome-based drug delivery technology in conjunction with the company's anti-sense nucleic acid cancer therapeutic. It's currently in Phase I clinical trials for treatment of various forms of leukemia and myelodysplastic syndrome. More here

> Greystone Research Associates: Transmucosal drug delivery gaining interest in niche markets. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.